Skip to main content
OpenTrials

Clinical trial condition

Corynebacterium Infections

Explore clinical trials studying Corynebacterium Infections. Study availability and eligibility vary by location and protocol.

233 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Corynebacterium Infections trial results

Completed

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

NCT00307567

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +32 more
Locations
  • GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bretten, Baden-Wurttemberg, Germany
  • GSK Investigational Site Eppelheim, Baden-Wurttemberg, Germany
  • GSK Investigational Site Kehl, Baden-Wurttemberg, Germany
View all 51 locations
View Trial Details
Completed

Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth

NCT00317122

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +20 more
Locations
  • GSK Investigational Site Brits, South Africa
  • GSK Investigational Site Brits, South Africa
  • GSK Investigational Site Centurion, South Africa
  • GSK Investigational Site Ga-Rankuwa, South Africa
View Trial Details
Completed

Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants

NCT00290303

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +21 more
Locations
  • GSK Investigational Site Manila, Philippines
  • GSK Investigational Site Quezon City, Philippines
  • GSK Investigational Site Sampaloc, Manila, Philippines
View Trial Details
Completed

Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety

NCT00263692

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Oakland, California, United States
  • GSK Investigational Site Torrance, California, United States
View all 15 locations
View Trial Details
Completed

Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.

NCT00263679

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Kehl, Baden-Wurttemberg, Germany
  • GSK Investigational Site Oberkirch, Baden-Wurttemberg, Germany
  • GSK Investigational Site Limburg an der Lahn, Hesse, Germany
  • GSK Investigational Site Erkrath, North Rhine-Westphalia, Germany
View all 13 locations
View Trial Details
Completed

Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)

NCT01294605

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Bruges, Belgium
  • GSK Investigational Site Leuven, Belgium
  • GSK Investigational Site Wilrijk, Belgium
  • GSK Investigational Site Rotterdam, Netherlands
View all 13 locations
View Trial Details

Related conditions